Within 30 months, Insilico Medicine’s ISM001-055, an AI-engineered inhibitor aimed against Traf2- and Nck-interacting kinase (TNIK) for idiopathic pulmonary fibrosis, progressed from concept to phase I trials, demonstrating the efficacy of AI in pharmaceutical development [199,200]. Here, MAP4K4 is linked to idiopathic pulmonary fibrosis.